The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC

Bookmark and Share
Published: 19 Dec 2019
Views: 419
Rating:
Save
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany

Dr Hans-Christian Kolberg speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the results from the ABP 980 LILAC trial looking at the importance of central pathology pCR review in an international multi-centre neoadjuvant study in HER2 positive early breast cancer.

He explains that, due to it being extremely difficult, most multi centre studies in neoadjuvant breast cancer do not complete central pathology pCR reviews.

Dr Kolberg was able to show that completing a central pathology pCR review is essential if you are using complex pCR definitions.